Denali Therapeutics Inc.
DNLI- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001714899
In the last 90 days, Denali Therapeutics Inc. insiders filed 0 open-market purchases and 4 sales; 294 institutions reported holding it in 13F filings for Q2 2026, worth $4.00B in total; no superinvestor holds it.
13F holders, Q3 2024
Institutional positions in Denali Therapeutics Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 217
- +16 vs. Q2 2024
- Shares held
- 126.8M
- +16.3M (+14.7%) vs. Q2 2024
- Total value
- $3.69B
- +$1.13B (+43.9%) vs. Q2 2024
- New holders
- 37
- 78 more added
- Sold out
- 21
- 59 more reduced
2 institutions that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DNLI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 294 | $4.00B |
| Q1 2026 | 269 | $2.82B |
| Q4 2025 | 250 | $2.50B |
| Q3 2025 | 240 | $1.97B |
| Q2 2025 | 231 | $1.93B |
| Q1 2025 | 222 | $1.85B |
| Q4 2024 | 224 | $2.61B |
| Q3 2024 | 217 | $3.69B |
| Q2 2024 | 203 | $2.88B |
| Q1 2024 | 211 | $2.51B |
| Q4 2023 | 209 | $2.47B |
| Q3 2023 | 195 | $2.24B |
| Q2 2023 | 203 | $3.18B |
| Q1 2023 | 202 | $2.49B |
| Q4 2022 | 199 | $2.94B |
| Q3 2022 | 200 | $2.84B |
| Q2 2022 | 188 | $2.73B |
| Q1 2022 | 190 | $2.79B |
| Q4 2021 | 213 | $3.80B |
| Q3 2021 | 214 | $4.28B |
| Q2 2021 | 210 | $6.32B |
| Q1 2021 | 218 | $4.60B |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Denali Therapeutics Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Farther Finance Advisors, LLC | 107 | $3.13K | 0.00% | +27+33.8% | Added |
| Bessemer Group Inc | 110 | $3.00K | 0.00% | +110 | New |
| Your Advocates Ltd., LLP | 100 | $2.91K | 0.00% | 00.0% | Unchanged |
| Capital Performance Advisors LLP | 63 | $1.83K | 0.00% | +63 | New |
| Ronald Blue Trust, Inc. | 72 | $1.67K | 0.00% | −10−12.2% | Reduced |
| Point72 (DIFC) Ltd | 55 | $1.61K | 0.00% | +55 | New |
| Bell Investment Advisors, Inc | 52 | $1.51K | 0.00% | 00.0% | Unchanged |
| AdvisorNet Financial, Inc | 40 | $1.17K | 0.00% | +40 | New |
| National Bank of Canada | 34 | $990 | 0.00% | +34 | New |
| CVA Family Office, LLC | 30 | $874 | 0.00% | 00.0% | Unchanged |
| First Horizon Advisors, Inc. | 25 | $728 | 0.00% | 00.0% | Unchanged |
| Principal Securities, Inc. | 23 | $670 | 0.00% | −122−84.1% | Reduced |
| Bokf, NA | 18 | $508 | 0.00% | +18 | New |
| Global Retirement Partners, LLC | 3 | $87 | 0.00% | −8−72.7% | Reduced |
| Toronto Dominion Bank | 2 | $58 | 0.00% | 00.0% | Unchanged |
| Avion Wealth | 25 | $0 | 0.00% | 00.0% | Unchanged |
| Hemington Wealth Management | 3 | $0 | 0.00% | +3 | New |
| Takeda Pharmaceutical Co Ltd | 0 | $0 | 0.00% | −4,214,559−100.0% | Sold out |
| Artal Group S.A. | 0 | $0 | 0.00% | −502,899−100.0% | Sold out |
| Vestal Point Capital, LP | 0 | $0 | 0.00% | −500,000−100.0% | Sold out |
| Integral Health Asset Management, LLC | 0 | $0 | 0.00% | −325,000−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −163,074−100.0% | Sold out |
| PDT Partners, LLC | 0 | $0 | 0.00% | −158,384−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −58,523−100.0% | Sold out |
| Woodline Partners LP | 0 | $0 | 0.00% | −56,554−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −54,056−100.0% | Sold out |
| Eisler Capital (US) LLC | 0 | $0 | 0.00% | −35,861−100.0% | Sold out |
| D. E. Shaw & Co., Inc. | 0 | $0 | 0.00% | −29,721−100.0% | Sold out |
| Hamilton Lane Advisors LLC | 0 | $0 | 0.00% | −25,657−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −24,390−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −11,130−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −10,343−100.0% | Sold out |
| Quarry LP | 0 | $0 | 0.00% | −6,500−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −862−100.0% | Sold out |
| Allworth Financial LP | 0 | $0 | 0.00% | −64−100.0% | Sold out |
| Valley National Advisers Inc | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Innealta Capital, LLC | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| CIBC Private Wealth Group, LLC | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |
| Susquehanna Fundamental Investments, LLC | – | – | – | – | Not filed |